These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14980230)

  • 21. [First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
    Einecke D
    MMW Fortschr Med; 2003 Dec; 145(51-52):38. PubMed ID: 14974329
    [No Abstract]   [Full Text] [Related]  

  • 22. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A safety look at currently available statins.
    Moghadasian MH
    Expert Opin Drug Saf; 2002 Sep; 1(3):269-74. PubMed ID: 12904142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins: effective antiatherosclerotic therapy.
    Blumenthal RS
    Am Heart J; 2000 Apr; 139(4):577-83. PubMed ID: 10740137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins: the new aspirin?
    Veillard NR; Mach F
    Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
    Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia.
    Davidson MH; Ballantyne CM; Kerzner B; Melani L; Sager PT; Lipka L; Strony J; Suresh R; Veltri E;
    Int J Clin Pract; 2004 Aug; 58(8):746-55. PubMed ID: 15372846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins: within-group comparisons, statin escape and combination therapy.
    Tikkanen MJ
    Curr Opin Lipidol; 1996 Dec; 7(6):385-8. PubMed ID: 9117143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Statins-a panacea?].
    Klose G
    Z Kardiol; 2004; 93 Suppl 1():I19-22. PubMed ID: 15022003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety review of combination drugs for hyperlipidemia.
    Farnier M
    Expert Opin Drug Saf; 2011 May; 10(3):363-71. PubMed ID: 21417957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The myotoxicity of statins.
    Evans M; Rees A
    Curr Opin Lipidol; 2002 Aug; 13(4):415-20. PubMed ID: 12151857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of statin therapy in patients with preexisting liver disease.
    Onofrei MD; Butler KL; Fuke DC; Miller HB
    Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.